Unusual radiologic manifestation of pseudoprogression in pulmonary metastases after durvalumab treatment in metastatic bladder urothelial cancer. Issue 4 (7th February 2019)

• Record Type: Journal Article
• Authors: Kim, Eun Young; Park, Inkeun; Kim, Young Saing; Ahn, Hee Kyung; Lee, Hee Young; Kim, Jeong Ho
• Is Part Of: Thoracic cancer. Volume 10:Issue 4(2019)
• Page Start: 1016
• Page End: 1018
• Publication Date: 2019-02-07
• Subjects: Bladder cancer -- durvalumab -- immunotherapy -- lung metastasis -- pseudoprogression; Chest -- Cancer -- Periodicals; Chest -- Cancer -- Treatment -- Periodicals; Chest -- Surgery -- Periodicals; 616.99494005
• DOI: 10.1111/1759-7714.12994
• Languages: English
• ISSNs: 1759-7706

Abstract

Abstract : Durvalumab is an immune checkpoint inhibitor that blocks PD‐L1. Unlike cytotoxic chemotherapy or molecularly targeted agents, immune checkpoint inhibitors occasionally present distinct response patterns, including radiologic pseudoprogression (initial tumor enlargement with subsequent tumor regression) and immune‐related adverse events in normal tissues. We report a case of unusual computed tomography (CT) findings of pseudoprogression of pulmonary metastases in a patient with metastatic bladder cancer after durvalumab treatment: multiple pulmonary metastases turned into ground‐glass opacity on first follow‐up CT; on second follow‐up CT, and after sustained treatment of the PD‐L1 inhibitor, the lesion was resolved.